Claims for Patent: 8,409,616
✉ Email this page to a colleague
Summary for Patent: 8,409,616
| Title: | Extended release opioid abuse deterrent compositions and methods of making same |
| Abstract: | This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix. |
| Inventor(s): | Kumar; Vijai (Morris Plains, NJ), Dixon; David (Woodside, NY), Tewari; Divya (Suffern, NY), Wadgaonkar; Dilip B. (Suffern, NY) |
| Assignee: | Acura Pharmaceuticals, Inc. (Palatine, IL) |
| Application Number: | 13/327,252 |
| Patent Claims: |
1. A therapeutic pharmaceutical composition comprising: a mixture including (a) a water soluble drug susceptible to abuse at about 0.5 to about 25 percent by weight; (b)
gel-forming polymer at about 3 to about 40 percent by weight; (c) a disintegrant at about 2 to 25 percent by weight wherein the disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and
(d) sorbitan monoester at about 1 to 10 percent by weight.
2. The therapeutic pharmaceutical composition of claim 1, wherein the gel-forming polymer is polyethylene oxide. 3. The therapeutic pharmaceutical composition of claim 2, wherein the polyethylene oxide has an average molecular weight ranging from 300,000 to about 5,000,000. 4. The therapeutic pharmaceutical composition of claim 1, wherein the sorbitan monoester is present in an amount of about 1 to about 3 percent by weight. 5. The therapeutic pharmaceutical composition of claim 1, wherein the disintegrant comprises croscarmellose sodium. 6. The therapeutic pharmaceutical composition of claim 1, further comprising microcrystalline cellulose. 7. The therapeutic pharmaceutical composition of claim 1, further comprising polyethylene glycol. 8. The therapeutic pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in unit dose form. 9. The therapeutic pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form. 10. A therapeutic pharmaceutical composition comprising: a mixture including (a) a water soluble drug susceptible to abuse; (b) a gel-forming polymer in an amount of about 3 to about 40 wt %; (c) a disintegrant; and (d) a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile. 11. The therapeutic pharmaceutical composition of claim 10, wherein the pharmaceutical composition is in unit dose form. 12. The therapeutic pharmaceutical composition of claim 10, wherein the pharmaceutical composition is in suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form. 13. The therapeutic pharmaceutical composition of claim 10, wherein the water soluble drug susceptible to abuse is present in an amount of 0.5 to about 25 wt % of the composition. 14. The therapeutic pharmaceutical composition of claim 10, wherein the disintegrant is present in an amount of about 2 to about 25 wt % of the composition. 15. The therapeutic pharmaceutical composition of claim 10, wherein the surfactant is present in an amount of about 1 to about 10 wt % of the composition. 16. The therapeutic pharmaceutical composition of claim 10, wherein the gel-forming polymer is present in an amount of about 3 to about 40 wt % of the composition. 17. The therapeutic pharmaceutical composition of claim 10, wherein the disintegrant is selected from the group consisting of sodium starch glycolate, crospovidone, and croscarmellose sodium. |
